“Guess what!? We’re in Raleigh/Durham for the State of the Science Summit on Hematologic Malignancies with @DukeCancer — going to be a fantastic night ahead!” tweeted OncLive, the official website for the Oncology Specialty Group whose mission it is to provide resources and information oncology professionals need to deliver the best patient care.
OncLive partnered with the Duke Division of Hematologic Malignancies and Cellular Therapy to host the educational summit in Durham on Wednesday night, May 1, featuring 15-minute presentations by Duke Cancer Institute blood cancer specialists Danielle Brander, MD; Nelson Chao, MD; Carlos DeCastro, MD; Harry Erba, MD; Ahmed Galal, MD; Yubin Kang, MD; Thomas LeBlanc, MD; Matthew McKinney, MD; Lindsay Rein, MD; Cristina Gasparetto, MD; and David Rizzieri, MD.
Gasparetto and Erba co-chaired the special event, held at the DoubleTree Hilton Raleigh Durham Airport hotel, which drew about 50 oncologists, fellows, nurse practitioners, nurses, and physician assistants from Duke and the community.
They learned about new scientific discoveries and novel treatment approaches in follicular lymphoma, Hodgkin's and non-Hodgkin's lymphoma, mantle cell lymphoma, acute and chronic myeloid leukemia (AML & CML), chronic and acute lymphocytic leukemia (ALL & CLL), multiple myeloma, severe aplastic anemia, and CAR-T cell therapy.
"The summit highlighted the breadth and depth of knowledge and clinical experience of our faculty," said Erba, who directs the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute. "Many from our own teams including nurses and advanced practice providers took time from their own personal lives to join us and learn more about the diseases we treat."
OncLive conducted several one-on-one interviews during the summit, which were featured in the days following the event OncLive website. Here are some of them below:
Attaining MRD Among Next Steps in the ALL Paradigm
Features Nelson Jen An Chao, MD
Targeted Therapies Advance Treatment in AML, But Toxicity Challenges Remain
Features Harry Erba, MD, PhD
TKI Discontinuation Still an Unclear Picture in CML
Features Lindsay A.M. Rein, MD
Expert Highlights Current State of Severe Aplastic Anemia
Features Carlos Manuel de Castro III, MD
Navigating Between High- and Low-Intensity Treatment Options in AML (OncLive)
Thomas W. LeBlanc, MD
Navigating the Complex Treatment Paradigm of Relapsed/Refractory Multiple Myeloma
Features Q & A with Cristina Gasparetto, MD
Novel Triplets, Potent Single Agents Emerge Across Myeloma Spectrum (OncLive)
Features Yubin Kang, MD
Pipeline Updates Advance Paradigms Across Lymphomas
Features Matthew McKinney, MD
Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma
Features Ahmed Galal, MD
Photos and videos courtesy of OncLive SOSS Twitter